Authors: DiNicolantonio JJ, Barroso-Aranda J, McCarty MF PMID: 33875563 PMCID: PMC8057070 DOI: 10.1136/openhrt-2021-001655 Abstract Ivermectin, a drug commonly used to treat a range of parasitic infections, has been shown to halve the mortality elicited by a fatal dose of lipopolysaccharide in mice, in an oral dose (4 mg/kg) that can be extrapolated to 2–4 times the [...]

The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness, hospitalizations, and death. The complex and multifaceted pathophysiology of life-threatening COVID-19 illness including viral mediated organ damage, cytokine storm, and thrombosis warrants early interventions to address all components of the devastating illness. In countries where therapeutic nihilism is prevalent, patients endure escalating symptoms and without early treatment can succumb to delayed in-hospital care and death.

Authors: DiNicolantonio JJ, Barroso-Arranda J, McCarty M PMID: 32895293 PMCID: PMC7476419 DOI: 10.1136/openhrt-2020-001350 Abstract Ivermectin, on the WHO’s List of Essential Medications, has been in clinical use since 1981 as an orally and topically active agent for treating a range of parasitic infections in humans, including river blindness and lymphatic filariasis. It is also widely [...]

Authors: Kjellberg A, De Maio A, Lindholm P PMID: 33254531 PMCID: PMC7456590 DOI: 10.1016/j.mehy.2020.110224 Abstract Introduction: SARS-CoV-2 affects part of the innate immune response and activates an inflammatory cascade stimulating the release of cytokines and chemokines, particularly within the lung. Indeed, the inflammatory response during COVID-19 is likely the cause for the development of acute [...]

Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital.

Authors: Menezes RR, Godin AM, Rodrigues FF, Coura GM, Melo IS, Brito AM PMID: 28958614 DOI: 10.1016/j.pharep.2017.04.011 Abstract Background: The effects induced by thiamine and riboflavin, isolated or in association with corticosteroids, in models of chronic inflammation are not known. Thus, we evaluated the effect induced by these B vitamins, isolated or in association with [...]

Authors: Yan S, Ci X, Chen N, Chen C, Li X, Chu X et al. PMID: 21279416 DOI: 10.1007/s00011-011-0307-8 Abstract Background and objective: Asthma is an inflammatory disease of the lungs that is characterised by increased inflammatory cell infiltration into the airways and poor respiratory function. Ivermectin is a semi-synthetic derivative of a family of [...]

Authors: Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N et al. PMID: 19453757 DOI: 10.1111/j.1472-8206.2009.00684.x Abstract Lipopolysaccharide (LPS) can induce mouse macrophages to produce a number of cytokines and other inflammatory mediators. Immunopharmacological studies can provide new information on the immunomodulatory activities of some drugs, including their effect on cytokine productions. [...]

Authors: Jacob A, Wu R, Zhou M, Wang P PMID: 18274631 PMCID: PMC2234255 DOI: 10.1155/2007/89369 Abstract Curcumin, the phytochemical component in turmeric, is used as a dietary spice and a topical ointment for the treatment of inflammation in India for centuries. Curcumin (diferuloylmethane) is relatively insoluble in water, but dissolves in acetone, dimethylsulphoxide, and ethanol. [...]